Following the announcement of a formal acquisition deal, Inozyme Pharma, Inc. (NASDAQ: INZY) shares jumped 178.17% as of the last check today to $3.95. INZY revealed that BioMarin Pharmaceutical will buy it for all cash for about $270 million.
Strategic Growth of BioMarin’s Portfolio of Rare Diseases
BioMarin will buy Inozyme at a price of $4.00 per share. The deal, anticipated to finalize in the third quarter of 2025, has received unanimous approval from the boards of directors of both businesses. The purchase is in line with BioMarin’s continuous plan to expand its line of enzyme replacement treatments, especially for uncommon and serious genetic disorders.
A Potential Treatment
INZ-701, Inozyme’s late-stage, first-in-class enzyme replacement treatment for ENPP1 Deficiency, is at the heart of this transaction. The circulatory system, soft tissues, and skeletal structure are all impacted by this uncommon and severe genetic condition, which has a significant risk of death, particularly in newborns. Later in adulthood, patients also have osteomalacia and rickets. In addition to ongoing or planned research for babies, adolescents, and adults, INZ-701 is presently undertaking critical Phase 3 trials in pediatric populations.
Enhancing Regulatory Routes and Clinical Development
Initial findings from INZ-701’s adult trials have been positive, with increases in important indicators including bone mineralization and pyrophosphate levels as well as a good safety profile. Data from the pediatric Phase 3 study is anticipated in early 2026, with a possible regulatory clearance date of 2027. For patients with ENPP1 Deficiency, this places INZ-701 as a potentially ground-breaking treatment that fills a major unmet need.
The Acquisition Process’s Next Steps
BioMarin plans to buy all of the outstanding shares of Inozyme common stock at $4.00 a share through a cash tender offer. Any remaining shares will be purchased through a merger with a BioMarin subsidiary when the tender is over, guaranteeing INZY’s complete integration into the BioMarin company.
Leave a Reply